Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion

Harbor-UCLA Medical Center, Saint John's Cardiovascular Research Center, Torrance 90509, USA.

OBJECTIVES: This study sought to determine the long-term effects of continuous infusion of epoprostenol (epo) therapy on survival and pulmonary artery pressure in patients with primary pulmonary hypertension (PPH). BACKGROUND: PPH is a progressive disease for which there are few effective therapies. METHODS: Patients with PPH and New York Heart Association functional class III or IV symptoms of congestive heart failure underwent right heart catheterization and Doppler-echocardiography to measure the maximal systolic pressure gradient between the right ventricle and right atrium (delta P) and cardiac output (CO). Doppler-echocardiography and catheterization data were compared. Patients were followed up long term with Doppler-echocardiography. RESULTS: Of 69 patients who went on to receive epo, 18 were followed up for > 330 days (range 330 to 700). During long-term follow-up, there was a significant reduction in delta P, which decreased from 84.1 +/- 24.1 to 62.7 +/- 18.2 (mean +/- SD, p < 0.01). A Kaplan-Meier plot of survival of our study patients demonstrated improved survival compared with that of historical control subjects. The 1-, 2- and 3-year survival rates for our patients were 80% (n = 36), 76% (n = 22) and 49% (n = 6) compared with 10- (88%, n = 31), 20- (56%, n = 27) and 30-month (47%, n = 17) survival rates in historical control subjects. CONCLUSIONS: Patients receiving continuous infusion of epo for treatment of PPH experience a decrease in pulmonary artery pressure. Long-term follow-up of this single-center patient group demonstrated improved long-term survival during epo therapy compared with that in historical control subjects and confirms predicted improved outcomes based on shorter follow-up periods.

This article has been cited by other articles:

				S. Bokhari, A. Raina, E. Berman Rosenweig, P. C. Schulze, J. Bokhari, A. J. Einstein, R. J. Barst, and L. L. Johnson PET Imaging May Provide a Novel Biomarker and Understanding of Right Ventricular Dysfunction in Patients With Idiopathic Pulmonary Arterial Hypertension Circ Cardiovasc Imaging, November 1, 2011; 4(6): 641 - 647. [Abstract] [Full Text] [PDF]

				R. J. Barst, S. I. Ertel, M. Beghetti, and D. D. Ivy Pulmonary arterial hypertension: a comparison between children and adults Eur. Respir. J., March 1, 2011; 37(3): 665 - 677. [Abstract] [Full Text] [PDF]

				J. F. Aduen, R. Castello, J. T. Daniels, J. A. Diaz, R. E. Safford, M. G. Heckman, J. E. Crook, and C. D. Burger Accuracy and Precision of Three Echocardiographic Methods for Estimating Mean Pulmonary Artery Pressure Chest, February 1, 2011; 139(2): 347 - 352. [Abstract] [Full Text] [PDF]

				D. Urboniene, I. Haber, Y.-H. Fang, T. Thenappan, and S. L. Archer Validation of high-resolution echocardiography and magnetic resonance imaging vs. high-fidelity catheterization in experimental pulmonary hypertension Am J Physiol Lung Cell Mol Physiol, September 1, 2010; 299(3): L401 - L412. [Abstract] [Full Text] [PDF]

				D. Montani, X. Jais, L. C. Price, L. Achouh, B. Degano, O. Mercier, S. Mussot, E. Fadel, P. Dartevelle, O. Sitbon, et al. Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease Eur. Respir. J., December 1, 2009; 34(6): 1348 - 1356. [Abstract] [Full Text] [PDF]

				D. B. Badesch, H. C. Champion, M. A. Gomez Sanchez, M. M. Hoeper, J. E. Loyd, A. Manes, M. McGoon, R. Naeije, H. Olschewski, R. J. Oudiz, et al. Diagnosis and Assessment of Pulmonary Arterial Hypertension J. Am. Coll. Cardiol., June 30, 2009; 54(1_Suppl_S): S55 - S66. [Abstract] [Full Text] [PDF]

				K. Boutet, D. Montani, X. Jais, A. Yaici, O. Sitbon, G. Simonneau, and M. Humbert Review: Therapeutic advances in pulmonary arterial hypertension Therapeutic Advances in Respiratory Disease, August 1, 2008; 2(4): 249 - 265. [Abstract] [PDF]

				S. Takaoka, J. L. Faul, and R. Doyle Current Therapies for Pulmonary Arterial Hypertension Seminars in Cardiothoracic and Vascular Anesthesia, June 1, 2007; 11(2): 137 - 148. [Abstract] [PDF]

				A. E Lammers, A. A Hislop, Y. Flynn, and S. G Haworth Epoprostenol treatment in children with severe pulmonary hypertension Heart, June 1, 2007; 93(6): 739 - 743. [Abstract] [Full Text] [PDF]

				T. Handa, S. Nagai, S. Miki, Y. Fushimi, K. Ohta, M. Mishima, and T. Izumi Incidence of Pulmonary Hypertension and Its Clinical Relevance in Patients With Sarcoidosis Chest, May 1, 2006; 129(5): 1246 - 1252. [Abstract] [Full Text] [PDF]

				L. J. Rubin and D. B. Badesch Evaluation and Management of the Patient with Pulmonary Arterial Hypertension Ann Intern Med, August 16, 2005; 143(4): 282 - 292. [Abstract] [Full Text] [PDF]

				H.-J. Seyfarth, H. Pankau, S. Hammerschmidt, J. Schauer, H. Wirtz, and J. Winkler Bosentan Improves Exercise Tolerance and Tei Index in Patients With Pulmonary Hypertension and Prostanoid Therapy Chest, August 1, 2005; 128(2): 709 - 713. [Abstract] [Full Text] [PDF]

				T. Nagaoka, K. A. Fagan, S. A. Gebb, K. G. Morris, T. Suzuki, H. Shimokawa, I. F. McMurtry, and M. Oka Inhaled Rho Kinase Inhibitors Are Potent and Selective Vasodilators in Rat Pulmonary Hypertension Am. J. Respir. Crit. Care Med., March 1, 2005; 171(5): 494 - 499. [Abstract] [Full Text] [PDF]

				M. Humbert, R.J. Barst, I.M. Robbins, R.N. Channick, N. Galie, A. Boonstra, L.J. Rubin, E.M. Horn, A. Manes, and G. Simonneau Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 Eur. Respir. J., September 1, 2004; 24(3): 353 - 359. [Abstract] [Full Text] [PDF]

				D. Yung, A. C. Widlitz, E. B. Rosenzweig, D. Kerstein, G. Maislin, and R. J. Barst Outcomes in Children With Idiopathic Pulmonary Arterial Hypertension Circulation, August 10, 2004; 110(6): 660 - 665. [Abstract] [Full Text] [PDF]

				R. J. Oudiz, A. Widlitz, X. J. Beckmann, D. Camanga, J. Alfie, B. H. Brundage, and R. J. Barst Micrococcus-Associated Central Venous Catheter Infection in Patients With Pulmonary Arterial Hypertension Chest, July 1, 2004; 126(1): 90 - 94. [Abstract] [Full Text] [PDF]

				M. McGoon, D. Gutterman, V. Steen, R. Barst, D. C. McCrory, T. A. Fortin, and J. E. Loyd Screening, Early Detection, and Diagnosis of Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines Chest, July 1, 2004; 126(1_suppl): 14S - 34S. [Abstract] [Full Text] [PDF]

				D. B. Badesch, S. H. Abman, G. S. Ahearn, R. J. Barst, D. C. McCrory, G. Simonneau, and V. V. McLaughlin Medical Therapy For Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines Chest, July 1, 2004; 126(1_suppl): 35S - 62S. [Abstract] [Full Text] [PDF]

				V. V. McLaughlin, K. W. Presberg, R. L. Doyle, S. H. Abman, D. C. McCrory, T. Fortin, and G. Ahearn Prognosis of Pulmonary Arterial Hypertension*: ACCP Evidence-Based Clinical Practice Guidelines Chest, July 1, 2004; 126(1_suppl): 78S - 92S. [Abstract] [Full Text] [PDF]

				D. B. Badesch, V. V. McLaughlin, M. Delcroix, C. Vizza, H. Olschewski, O. Sitbon, and R. J. Barst Prostanoid therapy for pulmonary arterial hypertension J. Am. Coll. Cardiol., June 16, 2004; 43(12_Suppl_S): 56S - 61S. [Abstract] [Full Text] [PDF]

				S. Yaqub, K. G. Moder, and M. Q. Lacy Severe, Reversible Pulmonary Hypertension in a Patient With Monoclonal Gammopathy and Features of Dermatomyositis Mayo Clin. Proc., May 1, 2004; 79(5): 687 - 689. [Abstract] [PDF]

				P. Bresser, P.F. Fedullo, W.R. Auger, R.N. Channick, I.M. Robbins, K.M. Kerr, S.W. Jamieson, and L.J. Rubin Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension Eur. Respir. J., April 1, 2004; 23(4): 595 - 600. [Abstract] [Full Text] [PDF]

				S C Apostolopoulou, S Rammos, Z S Kyriakides, D J Webb, N R Johnston, D V Cokkinos, and D T. Kremastinos Acute endothelin A receptor antagonism improves pulmonary and systemic haemodynamics in patients with pulmonary arterial hypertension that is primary or autoimmune and related to congenital heart disease Heart, October 1, 2003; 89(10): 1221 - 1226. [Abstract] [Full Text] [PDF]

				K. W Kenyon and J. M Nappi Bosentan for the Treatment of Pulmonary Arterial Hypertension Ann. Pharmacother., July 1, 2003; 37(7): 1055 - 1062. [Abstract] [Full Text] [PDF]

				R. J. Barst, M. McGoon, V. McLaughlin, V. Tapson, R. Oudiz, S. Shapiro, I. M. Robbins, R. Channick, D. Badesch, B. K. Rayburn, et al. Beraprost therapy for pulmonary arterial hypertension J. Am. Coll. Cardiol., June 18, 2003; 41(12): 2119 - 2125. [Abstract] [Full Text] [PDF]

				P. N. Kao and J. L. Faul Emerging therapies for pulmonary hypertension: Striving for efficacy and safety J. Am. Coll. Cardiol., June 18, 2003; 41(12): 2126 - 2129. [Full Text] [PDF]

				F. Ono, N. Nagaya, H. Okumura, Y. Shimizu, S. Kyotani, N. Nakanishi, and K. Miyatake Effect of Orally Active Prostacyclin Analogue on Survival in Patients With Chronic Thromboembolic Pulmonary Hypertension Without Major Vessel Obstruction Chest, May 1, 2003; 123(5): 1583 - 1588. [Abstract] [Full Text] [PDF]

				J Rodes-Cabau, E Domingo, A Roman, J Majo, B Lara, F Padilla, I Anivarro, J Angel, J C Tardif, and J Soler-Soler Intravascular ultrasound of the elastic pulmonary arteries: a new approach for the evaluation of primary pulmonary hypertension Heart, March 1, 2003; 89(3): 311 - 315. [Abstract] [Full Text] [PDF]

				K. P. Kuhn, D. W. Byrne, P. G. Arbogast, T. P. Doyle, J. E. Loyd, and I. M. Robbins Outcome in 91 Consecutive Patients with Pulmonary Arterial Hypertension Receiving Epoprostenol Am. J. Respir. Crit. Care Med., February 15, 2003; 167(4): 580 - 586. [Abstract] [Full Text] [PDF]

				A. Widlitz and R.J. Barst Pulmonary arterial hypertension in children Eur. Respir. J., January 1, 2003; 21(1): 155 - 176. [Abstract] [Full Text] [PDF]

				B. Raychaudhuri, A. Malur, T. L. Bonfield, S. Abraham, R. J. Schilz, C. F. Farver, M. S. Kavuru, A. C. Arroliga, and M. J. Thomassen The Prostacyclin Analogue Treprostinil Blocks NFkappa B Nuclear Translocation in Human Alveolar Macrophages J. Biol. Chem., August 30, 2002; 277(36): 33344 - 33348. [Abstract] [Full Text] [PDF]

				O. Sitbon, M. Humbert, H. Nunes, F. Parent, G. Garcia, P. Herve, M. Rainisio, and G.e. Simonneau Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: Prognostic factors and survival J. Am. Coll. Cardiol., August 21, 2002; 40(4): 780 - 788. [Abstract] [Full Text] [PDF]

				M.M. Hoeper, E. Spiekerkoetter, V. Westerkamp, R. Gatzke, and H. Fabel Intravenous iloprost for treatment failure of aerosolised iloprost in pulmonary arterial hypertension Eur. Respir. J., August 1, 2002; 20(2): 339 - 343. [Abstract] [Full Text] [PDF]

				M. Ueno, T. Miyauchi, S. Sakai, R. Yamauchi-Kohno, K. Goto, and I. Yamaguchi A combination of oral endothelin-areceptor antagonist and oral prostacyclinanalogue is superior to each drug alone inameliorating pulmonary hypertension in rats J. Am. Coll. Cardiol., July 3, 2002; 40(1): 175 - 181. [Abstract] [Full Text] [PDF]

				J.-L. Vachiery, N. Hill, D. Zwicke, R. Barst, S. Blackburn, and R. Naeije Transitioning From IV Epoprostenol to Subcutaneous Treprostinil in Pulmonary Arterial Hypertension* Chest, May 1, 2002; 121(5): 1561 - 1565. [Abstract] [Full Text] [PDF]

				M. M. Hoeper, N. Galie, G. Simonneau, and L. J. Rubin New Treatments for Pulmonary Arterial Hypertension Am. J. Respir. Crit. Care Med., May 1, 2002; 165(9): 1209 - 1216. [Full Text] [PDF]

				C D Vizza, S Sciomer, S Morelli, C Lavalle, P Di Marzio, D Padovani, R Badagliacca, A R Vestri, R Naeije, and F Fedele Long term treatment of pulmonary arterial hypertension with beraprost, an oral prostacyclin analogue Heart, December 1, 2001; 86(6): 661 - 665. [Abstract] [Full Text] [PDF]

				British Cardiac Society Guidelines and Medical Pra Recommendations on the management of pulmonary hypertension in clinical practice Heart, September 1, 2001; 86(90001): i1 - 13. [Full Text] [PDF]

				L. Appelbaum, M. Yigla, D. Bendayan, N. Reichart, G. Fink, I. Priel, Y. Schwartz, P. Richman, E. Picard, S. Goldman, et al. Primary Pulmonary Hypertension In Israel : A National Survey Chest, June 1, 2001; 119(6): 1801 - 1806. [Abstract] [Full Text] [PDF]

				H. Ting, X.-G. Sun, M.-L. Chuang, D. A. Lewis, J. E. Hansen, and K. Wasserman A Noninvasive Assessment of Pulmonary Perfusion Abnormality in Patients With Primary Pulmonary Hypertension Chest, March 1, 2001; 119(3): 824 - 832. [Abstract] [Full Text] [PDF]

				N. Galie Do we need controlled clinical trials in pulmonary arterial hypertension? Eur. Respir. J., January 1, 2001; 17(1): 1 - 3. [Full Text] [PDF]

				R. V. AGUILAR and H. W. FARBER Epoprostenol (Prostacyclin) Therapy in HIV-associated Pulmonary Hypertension Am. J. Respir. Crit. Care Med., November 1, 2000; 162(5): 1846 - 1850. [Abstract] [Full Text]

				R Ziesche, V Petkov, K Wittmann, J Kopatschka, L Stiebellehner, P Schenk, P Germann, G Roder, R Ullrich, and L H Block Treatment with epoprostenol reverts nitric oxide non-responsiveness in patients with primary pulmonary hypertension Heart, April 1, 2000; 83(4): 406 - 409. [Abstract] [Full Text]

				R J BARST Role of atrial septostomy in the treatment of pulmonary vascular disease Thorax, February 1, 2000; 55(2): 95 - 96. [Full Text]

				M. M. Hoeper, H. Olschewski, H. A. Ghofrani, H. Wilkens, J. Winkler, M. M. Borst, J. Niedermeyer, H. Fabel, W. Seeger, and the German PPH Study Group A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension J. Am. Coll. Cardiol., January 1, 2000; 35(1): 176 - 182. [Abstract] [Full Text] [PDF]

				I. M. Robbins, S. P. Gaine, R. Schilz, V. F. Tapson, L. J. Rubin, and J. E. Loyd Epoprostenol for Treatment of Pulmonary Hypertension in Patients With Systemic Lupus Erythematosus* Chest, January 1, 2000; 117(1): 14 - 18. [Abstract] [Full Text] [PDF]

				S. Rich and V. V. McLaughlin The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension J. Am. Coll. Cardiol., October 1, 1999; 34(4): 1184 - 1187. [Abstract] [Full Text] [PDF]

				N. Nagaya, M. Uematsu, Y. Okano, T. Satoh, S. Kyotani, F. Sakamaki, N. Nakanishi, K. Miyatake, and T. Kunieda Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension J. Am. Coll. Cardiol., October 1, 1999; 34(4): 1188 - 1192. [Abstract] [Full Text] [PDF]

				M. Aranda, K. K. Bradford, and R. G. Pearl Combined Therapy with Inhaled Nitric Oxide and Intravenous Vasodilators During Acute and Chronic Experimental Pulmonary Hypertension Anesth. Analg., July 1, 1999; 89(1): 152 - 152. [Abstract] [Full Text] [PDF]

				D. Langleben, R. J. Barst, D. Badesch, B. M. Groves, V. F. Tapson, S. Murali, R. C. Bourge, N. Ettinger, E. Shalit, L. M. Clayton, et al. Continuous Infusion of Epoprostenol Improves the Net Balance Between Pulmonary Endothelin-1 Clearance and Release in Primary Pulmonary Hypertension Circulation, June 29, 1999; 99(25): 3266 - 3271. [Abstract] [Full Text] [PDF]

				E. B. Rosenzweig, D. Kerstein, and R. J Barst Long-Term Prostacyclin for Pulmonary Hypertension With Associated Congenital Heart Defects Circulation, April 13, 1999; 99(14): 1858 - 1865. [Abstract] [Full Text] [PDF]

				R. J. Barst, G. Maislin, and A. P. Fishman Vasodilator Therapy for Primary Pulmonary Hypertension in Children Circulation, March 9, 1999; 99(9): 1197 - 1208. [Abstract] [Full Text] [PDF]

				PROSTACYCLIN ANALOGUE THERAPY FOR PRIMARY PULMONARY HYPERTENSION Journal Watch (General), August 19, 1997; 1997(819): 2 - 2. [Full Text]